|
Therapeutic management, delivery, and postpartum risk assessment and screening in gestational diabetes |
Nicholson WK, Wilson LM, Witkop CT, Baptiste-Roberts K, Bennett WL, Bolen S, Barone BB, Golden SH, Gary TL, Neale DM, Bass EB |
|
|
Citation Nicholson WK, Wilson LM, Witkop CT, Baptiste-Roberts K, Bennett WL, Bolen S, Barone BB, Golden SH, Gary TL, Neale DM, Bass EB. Therapeutic management, delivery, and postpartum risk assessment and screening in gestational diabetes. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 162. 2008 Authors' objectives <p>We focused on four questions: (1) What are the risks and benefits of an oral diabetes agent (i.e., glyburide), as compared to all types of insulin, for gestational diabetes? (2) What is the evidence that elective labor induction, cesarean delivery, or timing of induction is associated with benefits or harm to the mother and neonate? (3) What risk factors are associated with the development of type 2 diabetes after gestational diabetes? (4) What are the performance characteristics of diagnostic tests for type 2 diabetes in women with gestational diabetes?</p> Authors' conclusions The evidence suggests that benefits and a low likelihood of harm are associated with the treatment of gestational diabetes with an oral diabetes agent or insulin. The effect of induction or elective cesarean on outcomes is unclear. The evidence is consistent that anthropometry identifies women at risk of developing subsequent type 2 diabetes; however, no evidence suggested the FBG out-performs the 75-gm OGTT in diagnosing type 2 diabetes after delivery. Indexing Status Subject indexing assigned by CRD MeSH Delivery, Obstetric; Diabetes, Gestational; Disease Management; Female; Humans; Postpartum Period; Pregnancy; Risk Assessment Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639 Email: martin.erlichman@ahrq.hhs.gov AccessionNumber 32008100009 Date abstract record published 09/08/2008 |
|
|
|